Consensus Immunic, Inc.

Stocks

IMUX

US4525EP2001

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-21 EDT			5-day change	1st Jan Change
7.480 ^USD	+0.94%		+12.31%	+40.15%

09-11	Immunic, Inc. Announces Resignation of Duane Nash as Member of the Board of Directors	CI
09-09	Immunic, Inc. - Special Call

Evolution of the Average Target: Immunic, Inc.

Evolution of the Target Price: Immunic, Inc.

Changes in Analyst Recommendations: Immunic, Inc.

c6f502e74668190218e916.tZS6FgSRMujHua_CUPAdibRFI_OErZ5TUonj3ZT33uQ.8vrTZlPkQd6IlPeRJsV-x8cMbKG979NqFO2m6-LCtqPC-dBOQd9Z3f-J9g~b1b146f9be243d7084f362720a5ccda9

Analysts' recommendations: Immunic, Inc.

09-01	Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating	MT
08-17	Wedbush Initiates Immunic at Outperform With $45 Price Target	MT
05-22	B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating	MT
04-17	Stifel Nicolaus Initiates Coverage on Immunic With Buy Rating, $2.50 Price Target	MT
03-24	Guggenheim Initiates Coverage on Immunic With Buy Rating, $7 Price Target	MT
11-07	Roth Capital Initiates Coverage on Immunic With Buy Rating, $3 Price Target	MT
25-09-29	Chardan Initiates Immunic at Buy With $3 Price Target	MT
25-09-02	B. Riley Cuts Price Target on Immunic to $4 From $5, Keeps Buy Rating	MT
25-05-23	B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating	MT
25-03-25	William Blair Initiates Immunic at Outperform With $6.80 Price Target	MT
24-08-27	B. Riley Securities Initiates Immunic at Buy With $6 Price Target	MT
24-02-23	Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	MT
23-10-10	Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	MT
23-01-31	Wedbush Assumes Coverage of Immunic With Outperform Rating, Lowers Price Target to $5 From $7	MT
22-10-21	SVB Securities Downgrades Immunic to Market Perform From Outperform, Adjusts Price Target to $5 From $9	MT
22-10-21	Wedbush Adjusts Immunic's Price Target to $7 From $11 on Stock Dilution, Keeps Outperform Rating	MT
22-09-19	HC Wainwright Assumes Immunic at Buy with $26 Price Target	MT
22-08-05	Wedbush Adjusts Immunic's Price Target to $11 From $14, Keeps Outperform Rating	MT
22-06-03	SVB Securities Adjusts Immunic's Price Target to $9 From $45, Keeps Outperform Rating	MT
22-06-03	Wedbush Adjusts Immunic's Price Target to $14 From $61, Removing IMU-838/Ulcerative Colitis From Model; Outperform Rating Kept	MT
22-05-18	Piper Sandler Adjusts Immunic's Price Target to $39 From $71, Reiterates Overweight Rating	MT
21-09-07	Immunic : HC Wainwright Adjusts Immunic's Price Target to $25 from $40, Keeps Buy Rating	MT
21-08-09	Immunic : Wedbush Adjusts Immunic's Price Target to $61 From $68, Citing Stock Dilution; Outperform Rating Kept	MT
21-07-06	Immunic : Wedbush Trims Immunic's Price Target to $68 From $72 on Adjusted IMU-838/RRMS Timeline; Outperform Rating Kept	MT
21-04-15	Immunic : Aegis Capital Initiates Immunic at Buy Rating With $55 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IMMUNIC, INC.					+481.52%
	WUXI APPTEC CO., LTD.					+29.95%
	ARGENX SE					+29.38%
	LONZA GROUP AG					+11.46%
	IQVIA HOLDINGS INC.					+12.36%
	BEONE MEDICINES AG					+13.51%
	REVOLUTION MEDICINES, INC.					+31.18%
	CELLTRION, INC.					+35.68%
	WUXI BIOLOGICS (CAYMAN) INC.					+20.18%
	GENMAB A/S					+6.68%
	Average					+67.19%
	Weighted average by Cap.					+22.13%